Ibeagha-Awemu Eveline M, Ibeagha Aloysius E, Zhao Xin
Department of Animal Science, McGill University, Quebec, Canada.
BMC Res Notes. 2012 Feb 14;5:93. doi: 10.1186/1756-0500-5-93.
Membrane-CD14 (mCD14) is expressed on the surface of monocytes, macrophages and polymorphonuclear neutrophil leukocytes (PMN). mCD14 acts as a co-receptor along with Toll like receptor 4 (TLR 4) and MD-2 for the detection of lipopolysaccharide (LPS). However, studies using different sample preparation methods and anticoagulants have reported different levels of mCD14 on the surface of monocytes and neutrophils. In this study, the influence of various anticoagulants and processing methods on measurement of mCD14 on monocytes and neutrophils was examined.
Whole blood samples were collected in vacutainer tubes containing either sodium heparin (HEPARIN), ethylenediaminetetraacetic acid (EDTA) or sodium citrate (CITRATE). mCD14 on neutrophils and monocytes in whole blood samples or isolated cells was measured by the method of flow cytometry using fluorescein isothiocyanate (FITC)-labeled monoclonal antibody. There was a significant difference (p < 0.05) in the mean channel fluorescence intensity (MFI) of mCD14 on neutrophils in whole blood samples anticoagulated with HEPARIN (MFI = 64.77) in comparison with those in whole blood samples anticoagulated with either EDTA (MFI = 38.25) or CITRATE (MFI = 43.7). The MFI of mCD14 on monocytes in whole blood samples anticoagulted with HEPARIN (MFI = 206.90) was significantly higher than the MFI in whole blood samples anticoagulated with EDTA (MFI = 149.37) but similar to that with CITRATE (MFI = 162.55). There was no significant difference in the percentage of whole blood neutrophils or monocytes expressing mCD14 irrespective of type of anticoagulant used. However, MFI of mCD14 on monocytes was about 3.2-folds (HEPARIN), 3.9-folds (EDTA) or 3.7 folds (CITRATE) higher than those on neutrophils. Furthermore, there was no significant difference in mCD14 levels between unprocessed whole blood monocytes and monocytes in peripheral blood mononuclear cell preparation. Conversely, a highly significant difference was observed in mCD14 between unprocessed whole blood neutrophils and isolated neutrophils (p < 0.05).
From these results, it is suggested that sodium heparin should be the preferred anticoagulant for use in the reliable quantification of the surface expression of mCD14. Furthermore, measurement of mCD14 is best carried out in whole blood samples, both for neutrophils and monocytes.
膜型CD14(mCD14)表达于单核细胞、巨噬细胞和多形核中性粒细胞(PMN)表面。mCD14作为Toll样受体4(TLR 4)和MD - 2的共同受体,用于检测脂多糖(LPS)。然而,使用不同样本制备方法和抗凝剂的研究报道了单核细胞和中性粒细胞表面mCD14的水平不同。在本研究中,考察了各种抗凝剂和处理方法对单核细胞和中性粒细胞上mCD14测量的影响。
将全血样本采集于含有肝素钠(HEPARIN)、乙二胺四乙酸(EDTA)或柠檬酸钠(CITRATE)的真空采血管中。使用异硫氰酸荧光素(FITC)标记的单克隆抗体,通过流式细胞术方法测量全血样本或分离细胞中中性粒细胞和单核细胞上的mCD14。与用EDTA(平均通道荧光强度[MFI]=38.25)或CITRATE(MFI = 43.7)抗凝的全血样本相比,用HEPARIN抗凝的全血样本中中性粒细胞上mCD 的MFI有显著差异(p<0.05)(MFI = 64.77)。用HEPARIN抗凝的全血样本中单核细胞上mCD14的MFI(MFI = 206.90)显著高于用EDTA抗凝的全血样本中的MFI(MFI = 149.37),但与用CITRATE抗凝的样本相似(MFI = 162.55)。无论使用何种抗凝剂,全血中表达mCD14的中性粒细胞或单核细胞百分比均无显著差异。然而,单核细胞上mCD14的MFI比中性粒细胞上的高约3.2倍(HEPARIN)、3.9倍(EDTA)或3.7倍(CITRATE)。此外,未处理的全血单核细胞与外周血单核细胞制备物中的单核细胞之间mCD14水平无显著差异。相反,未处理的全血中性粒细胞与分离的中性粒细胞之间mCD14存在高度显著差异(p<0.05)。
从这些结果表明,肝素钠应是可靠定量mCD14表面表达时的首选抗凝剂。此外,对于中性粒细胞和单核细胞,mCD14的测量最好在全血样本中进行。